Perspective Therapeutics develops radiopharmaceutical treatments using targeted alpha therapy to treat various cancers, including neuroendocrine tumors, melanoma, and prostate cancer. The company's pipeline includes VMT-a-NET for somatostatin receptor-positive neuroendocrine tumors, VMT01 for melanoma, PSV359 targeting fibroblast activation protein, and Pluvicto for metastatic prostate cancer, with several candidates currently in Phase 1/2a clinical trials. The company also collaborates with Bristol Myers Squibb on a combination study involving one of its therapies with an immunotherapy agent.
1Y: 1.15 (-57.9%) · range 1.15–5.65
entry readiness 80 · STRONG SETUP · exit proximity 0
Value area 2.44–3.62 · 96% of 120d volume overhead · heavy supply
No source detections in the last 21 days.
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -10.28% | +2.80% | mature |
| 40d | -32.40% | +2.80% | mature |